Harvard Bioscience, Inc.HBIONASDAQ
LOADING
|||
Operating Income Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
124.05%
↑ 101% above average
Average (39q)
-11582.85%
Historical baseline
Range
High:1414.29%
Low:-451627.27%
CAGR
+0.2%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 124.05% |
| Q2 2025 | 98.35% |
| Q1 2025 | -451627.27% |
| Q4 2024 | 100.59% |
| Q3 2024 | 9.42% |
| Q2 2024 | 9.21% |
| Q1 2024 | -908.16% |
| Q4 2023 | 130.23% |
| Q3 2023 | -217.21% |
| Q2 2023 | -54.49% |
| Q1 2023 | 482.71% |
| Q4 2022 | 87.85% |
| Q3 2022 | -194.10% |
| Q2 2022 | 159.56% |
| Q1 2022 | -495.06% |
| Q4 2021 | 210.04% |
| Q3 2021 | 844.83% |
| Q2 2021 | 124.27% |
| Q1 2021 | -108.67% |
| Q4 2020 | 1414.29% |
| Q3 2020 | -67.27% |
| Q2 2020 | 116.99% |
| Q1 2020 | -300.31% |
| Q4 2019 | 219.71% |
| Q3 2019 | -698.68% |
| Q2 2019 | 570.59% |
| Q1 2019 | -98.05% |
| Q4 2018 | 95.73% |
| Q3 2018 | 332.98% |
| Q2 2018 | 69.83% |
| Q1 2018 | -288.11% |
| Q4 2017 | 594.85% |
| Q3 2017 | -13700.00% |
| Q2 2017 | 100.16% |
| Q1 2017 | 43.10% |
| Q4 2016 | -38.13% |
| Q3 2016 | 3.21% |
| Q2 2016 | -280.09% |
| Q1 2016 | -295.58% |
| Q4 2015 | 114.58% |